Search for: "Astrazeneca"
Results 821 - 840
of 1,246
Sort by Relevance
|
Sort by Date
5 Aug 2010, 2:22 am
AstraZeneca agreed earlier to pay $2 million to settle more than 200 Seroquel cases, averaging about $10,000 each. [read post]
30 Jul 2010, 4:06 am
Jackson v. [read post]
28 Jul 2010, 12:06 am
(Patent Docs) Crestor (Rosuvastatin) – US: Patent infringement complaint following amended ANDA filing: AstraZeneca Pharmaceuticals LP et al. v. [read post]
20 Jul 2010, 12:58 pm
In April of 2010, AstraZeneca LP and AstraZeneca Pharmaceuticals agreed to pay $520 million to resolve claims that the company marketed the drug Seroquel for off-label purposes and provided kick-backs to doctors who promoted its use. [read post]
20 Jul 2010, 6:00 am
New York state reached a settlement for $45 million as part of a $520 million federal and multi-state agreement with AstraZeneca concerning allegations that the company provided kickbacks to doctors and engaged in an off-label marketing campaign to promote its antipsychotic drug Seroquel. [read post]
17 Jul 2010, 7:24 am
., AstraZeneca Pharms. [read post]
16 Jul 2010, 12:10 pm
., AstraZeneca Pharms. [read post]
15 Jul 2010, 2:28 am
Unlike the AstraZeneca case, this case does not involve allegations of misuse of market power relating to a patented product; it concerns allegations about a price-fixing cartel for rubber compounds. [read post]
14 Jul 2010, 6:47 pm
(Patent Docs) Losec (Omeprazole) – EU: SPCs and anticompetitive conduct: the General Court speaks: AstraZeneca v Commission (SPC blog) (IP Whiteboard) Monovisc – US: Patent infringement complaint based on manufacture and sale of Monovisc: Genzyme Corp. v. [read post]
13 Jul 2010, 2:31 am
321/05 AstraZeneca AB v Commission which has been conveniently summarised by Linklaters and Gibson Dunn. [read post]
7 Jul 2010, 6:01 am
AstraZeneca’s scheme was wildly successful. [read post]
7 Jul 2010, 5:14 am
(Patent Docs) (Holman's Biotech IP Blog) US: AMP v USPTO after Bilski v Kappos (Patent Docs) US: NORD Chair/HP&M Director presents opening testimony at first ever FDA orphan drug hearing (FDA Law Blog) US: Celsis files patent infringement complaint against CellzDirect and Invitrogen over pooled multi-cryopreserved hepatocyte products (Patent Docs) Products Astelin (Azelastine) – US: Zydus admits infringing Meda’s Astelin patent, agrees not to market generic (Patent Docs)… [read post]
6 Jul 2010, 6:03 pm
(Patent Docs) (Holman’s Biotech IP Blog) US: AMP v USPTO after Bilski v Kappos (Patent Docs) US: NORD Chair/HP&M Director presents opening testimony at first ever FDA orphan drug hearing (FDA Law Blog) US: Celsis files patent infringement complaint against CellzDirect and Invitrogen over pooled multi-cryopreserved hepatocyte products (Patent Docs) Products Astelin (Azelastine) – US: Zydus admits infringing Meda’s Astelin patent, agrees not to market generic (Patent Docs)… [read post]
6 Jul 2010, 1:03 am
Erstens habe AstraZeneca vor nationalen Patentämtern irreführende Angaben gemacht. [read post]
2 Jul 2010, 5:28 am
" AstraZeneca Pharm. [read post]
1 Jul 2010, 1:32 pm
Grassley letters are available in the continuation of this blog entryBelow are links to the letters sent by Grassley to: Abbott Laboratories Amgen AstraZeneca Pharmaceuticals Boehringer Bristol-Myers Squibb Company Eisai Corporation of America Eli Lilly and Company Forest Laboratories GlaxoSmithKline Hoffman-La Roche Inc. [read post]
1 Jul 2010, 6:30 am
”The company also has a chief compliance officer reporting to the CEO, a corporate compliance committee, a code of conduct, a compliance hotline and extensive procedures to investigate and remediate possible non-compliance, he said.Anonymous ReportsTony Jewell, a U.S. spokesman for London-based AstraZeneca, the U.K. [read post]
1 Jul 2010, 6:00 am
If you're too busy to read all 920 paragraphs of Case T-321/05 AstraZeneca v Commission, delivered today by the General Court of the European Union, let the IPKat help you at least find out what all the fuss is about. [read post]
30 Jun 2010, 5:52 am
(Docket Report) US: Update on reverse settlement agreements – Amici curiae brief filed with US Court of Appeals: In re Ciprofloxacin Hydrochloride Antitrust Litigation (IP Whiteboard) (PatLit) US: An uneven debate on ‘takings’ in pharmaceutical patent law (Patent Docs) Products Aldara (Imiquimod) – US: Graceway’s injunction and Nycomed’s dismissal denied in Aldara suit (Patent Docs) Argatroban – US: Patent for Argatroban found valid, injunction issued… [read post]
29 Jun 2010, 6:01 pm
(Docket Report) US: Update on reverse settlement agreements – Amici curiae brief filed with US Court of Appeals: In re Ciprofloxacin Hydrochloride Antitrust Litigation (IP Whiteboard) (PatLit) US: An uneven debate on ‘takings’ in pharmaceutical patent law (Patent Docs) Products Aldara (Imiquimod) – US: Graceway’s injunction and Nycomed’s dismissal denied in Aldara suit (Patent Docs) Argatroban – US: Patent for Argatroban found valid, injunction… [read post]
